Riding on positive data, argenx raises $1.1B while Alzheimer’s biotech Acumen lands $130M

An im­munol­o­gy play­er and an Alzheimer’s biotech each have a big boost in cash — a mas­sive $1.1 bil­lion for ar­genx and $130 mil­lion for Acu­men Phar­ma­ceu­ti­cals — af­ter sell­ing mil­lions of shares.

Ar­genx $ARGX says it ex­pects to raise $1.1 bil­lion in a mixed pub­lic and pri­vate glob­al of­fer­ing, in­clud­ing 1.5 mil­lion shares of Amer­i­can De­pos­i­to­ry Shares sold for $490 each and 663,918 or­di­nary shares for €436.37 each in a pri­vate place­ment in Eu­rope and the UK.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN